Mainz: At the third CRI-CIMT-EATI-AACR international cancer immunotherapy conference held in Mainz recently, one of the emerging themes from an exciting and interesting meeting was novel cancer vaccines.
Despite the announcement last month that the Bavarian-Nordic phase 3 PROSTVAC trial in prostate cancer was futile (See post: PROSPECTing for nuggets with PROSTVAC in CRPC), therapeutic cancer vaccine research is experiencing a renaissance.
In this new mini-series, we’re featuring interviews with leading scientists and clinical researchers at the forefront of cancer vaccine research.
It’s not meant to be an exhaustive list of the “good and great,” as not all leaders in the field were actually in Mainz, but nonetheless we hope this series, like a series of postcards, captures some of the excitement along with challenges and opportunities facing researchers at present.
Up next is Professor Cornelius “Kees” Melief, who is Emeritus Professor at Leiden University in the Netherlands and Chief Scientific Officer of ISA Pharmaceuticals – where ISA stands for Immune System Activation.
Earlier this year, Professor Melief received a lifetime achievement award from the Association for Cancer Immunotherapy (CIMT) for his work in research in this niche.
He’s a global expert on cancer vaccine research. Ironically, back in July he published an editorial in Nature entitled, “Cancer: Precision T-Cell therapy targets tumors” that discussed some two letters on neoantigen cancer vaccine research from other thought leaders we have interviewed in this current mini-series, namely Dr Cathy Wu (Link) and Prof Ugur Sahin (Link).
While, in Mainz, Professor Melief kindly shared his thoughts on the field, where it is going, and how ISA Pharmaceuticals are looking to make a difference. Here’s an audio postcard for those interested in hearing a sample of what he had to say…
This is the fourth interview in our mini-series on the Future of Cancer Vaccines.